臨床外科74巻9号

2019年09月発行

特集 膵・消化管神経内分泌腫瘍—診断・治療の基本と最新動向

遺伝性疾患に合併する膵・消化管神経内分泌腫瘍の診断と手術

著者： 木村康利¹ 今村将史¹ 永山稔¹ 山口洋志¹ 村上武士¹ 吉田幸平¹ 沖田憲司¹ 西舘敏彦¹ 信岡隆幸¹ 櫻井晃洋² 竹政伊知朗¹

所属機関： ¹札幌医科大学医学部消化器・総合，乳腺・内分泌外科学講座 ²札幌医科大学医学部遺伝医学

ページ範囲：P.1085 - P.1090

文献概要

【ポイント】
◆MEN1やVHLでは多発性の小さな膵NETを伴うことがあり，確定診断としてEUS/FNAやソマトスタチン受容体シンチグラフィが有用である．
◆MEN1の機能性NETには外科的治療が推奨され，非機能性膵NETには腫瘍径2 cm以上で手術を考慮する．
◆手術適応と術式の決定には腫瘍の数と局在および内分泌症状の有無を考慮し，膵切除には可能な限り膵機能を温存する術式を考慮する．

参考文献

1）笹野公伸，笠島敦了：膵臓神経内分泌腫瘍（PNET）の遺伝子変異．肝胆膵66：765-770，2013

2）櫻井晃洋：膵神経内分泌腫瘍と遺伝性疾患．胆と膵38：1357-1362，2017

3）Ito T, Igarashi H, Nakamura K, et al：Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan：a nationwide survey analysis. J Gastroenterol 50：58-64, 2015

4）Sakurai A, Suzuki S, Kosugi S, et al：MEN Consortium of Japan. Multiple endocrine neoplasia type 1 in Japan：Establishment and analysis of a multicentre database. Clin Endocrinol（Oxf）76：533-539, 2012

5）Gibril F, Schumann M, Pace A, et al：Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome：a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine（Baltimore）83：43-83, 2004

6）Sakurai A, Yamazaki M, Suzuki S, et al：Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1：analysis of the database of the MEN Consortium of Japan. Endocr J 59：859-866, 2012

7）Goudet P, Murat A, Binquet C, et al：Risk factors and causes of death in MEN1 disease. A GTE（Groupe d'Etude des Tumeurs Endocrines）cohort study among 758 patients. World J Surg 34：249-255, 2010

8）Ganeshan D, Menias CO, Pickhardt PJ, et al：Tumors in von Hippel-Lindau syndrome：from head to toe-comprehensive state-of-the-art review. Radiographics 38：849-866, 2018

9）医療における遺伝学的検査・診断に関するガイドライン．http://jams.med.or.jp/guideline/genetics-diagnosis.pdf

10）van Treijen MJC, van Beek DJ, van Leeuwaarde RS, et al：Diagnosing nonfunctional pancreatic nets in MEN1：the evidence base. J Endocr Soc 2：1067-1088, 2018

11）Kann PH：Is endoscopic ultrasonography more sensitive than magnetic resonance imaging in detecting and localizing pancreatic neuroendocrine tumors? Rev Endocr Metab Disord 19：133-137, 2018

12）執印太郎，宝金清博，西川　亮，他，フォン・ヒッペル・リンドウ病の病態調査と診断治療系確立の研究班（編）；フォン・ヒッペル・リンドウ（VHL）病診療ガイドライン．中外医学社，2011

13）Ito T, Jensen RT：Imaging in multiple endocrine neoplasia type 1：recent studies show enhanced sensitivities but increased controversies. Int J Endocr Oncol 3：53-66, 2016

14）Thakker RV, Newey PJ, Walls GV, et al：Clinical practice guidelines for multiple endocrine neoplasia type 1（MEN1）. J Clin Endocrinol Metab 97：2990-3011, 2012

15）Falconi M, Eriksson B, Kaltsas G, et al：ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors. Neuroendocrinology 103：153-171, 2016

16）Partelli S, Tamburrino D, Lopez C, et al：Active surveillance versus surgery of nonfunctioning pancreatic neuroendocrine neoplasms ＜/＝2 cm in men1 patients. Neuroendocrinology 103：779-786, 2016

17）Triponez F, Sadowski SM, Pattou F, et al：Long-term follow-up of MEN1 patients who do not have initial surgery for small ≤2 cm nonfunctioning pancreatic neuroendocrine tumors, an AFCE and GTE study：Association Francophone de Chirurgie Endocrinienne ＆ Groupe d'Etude des Tumeurs Endocrines. Ann Surg 268：158-164, 2018

18）Pieterman CRC, de Laat JM, Twisk JWR, et al：Long-term natural course of small nonfunctional pancreatic neuroendocrine tumors in MEN1-results from the Dutch MEN1 study group. J Clin Endocrinol Metab 102：3795-3805, 2017

19）Donegan D, Singh Ospina N, et al：Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. Clin Endocrinol（Oxf）86：199-206, 2017

20）Gibril F, Venzon DJ, Ojeaburu JV, et al：Prospective study of the natural history of gastrinoma in patients with MEN1：definition of an aggressive and a nonaggressive form. J Clin Endocrinol Metab 86：5282-5293, 2001

21）Fraker DL, Norton JA, Alexander HR, et al：Surgery in Zollinger-Ellison syndrome alters the natural history of gastrinoma. Ann Surg 220：320-328, discussion 328-330, 1994

22）Norton JA, Fraker DL, Alexander HR, et al：Surgery increases survival in patients with gastrinoma. Ann Surg 244：410-419, 2006

23）Bartsch DK, Fendrich V, Langer P, et al：Outcome of duodenopancreatic resections in patients with multiple endocrine neoplasia type 1. Ann Surg 242：757-764, 2005

24）Imamura M, Komoto I, Ota S, et al：Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients. World J Gastroenterol 17：1343-1353, 2011

25）Albers MB, Manoharan J, Bollmann C, et al：Results of duodenopancreatic reoperations in multiple endocrine neoplasia type 1. World J Surg 43：552-558, 2019

26）Tonelli F, Giudici F, Nesi G, et al：Operation for insulinomas in multiple endocrine neoplasia type 1：When pancreato-duodenectomy is appropriate. Surgery 161：727-734, 2017

27）Vezzosi D, Cardot-Bauters C, Bouscaren N, et al：Long-term results of the surgical management of insulinoma patients with MEN1：a Groupe d'etude des Tumeurs Endocrines（GTE）retrospective study. Eur J Endocrinol 172：309-319, 2015

28）Lopez CL, Albers MB, Bollmann C, et al：Minimally invasive versus open pancreatic surgery in patients with multiple endocrine neoplasia type 1. World J Surg 40：1729-1736, 2016

29）Maeda H, Hanazaki K：Pancreatogenic diabetes after pancreatic resection. Pancreatology 11：268-276, 2011

30）Jethwa P, Sodergren M, Lala A, et al：Diabetic control after total pancreatectomy. Dig Liver Dis 38：415-419, 2006

31）Shah MH, Goldner WS, Halfdanarson TR, et al：NCCN guidelines insights：neuroendocrine and adrenal tumors, version 2.2018. J Natl Compr Canc Netw 16：693-702, 2018

32）Lonser RR, Glenn GM, Walther M, et al：von Hippel-Lindau disease. Lancet 361：2059-2067, 2003

33）Yamasaki I, Nishimori I, Ashida S, et al：Clinical characteristics of pancreatic neuroendocrine tumors in Japanese patients with von Hippel-Lindau disease. Pancreas 33：382-385, 2006

34）Igarashi H, Ito T, Nishimori I, et al：Pancreatic involvement in Japanese patients with von Hippel-Lindau disease：results of a nationwide survey. J Gastroenterol 49：511-516, 2014

35）Binderup ML, Bisgaard ML, Harbud V, et al：Von Hippel-Linadu disease（vHL）. National clinical guideline for diagnosis and surveillance in Denmark. 3rd edition. Dan Med J 60：B4763, 2013

36）Ganeshan D, Menias CO, Pickhardt PJ, et al：Tumors in von Hippel-Lindau syndrome：from head to toe-comprehensive state-of-the-art review. Radiographics 38：849-866, 2018

37）Keutgen XM, Hammel P, Choyke PL, et al：Evaluation and management of pancreatic lesions in patients with von Hippel-Lindau disease. Nat Rev Clin Oncol 13：537-549, 2016

38）Blansfield JA, Choyke L, Morita SY, et al：Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease（VHL）manifested by pancreatic neuroendocrine neoplasms（PNETs）. Surgery 142：814-818, 2007

39）Krauss T, Ferrara AM, Links TP, et al：Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer 25：783-793, 2018

40）Tirosh A, Sadowski SM, Linehan WM, et al：Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol 4：124-126, 2018

41）Ito T, Sasano H, Tanaka M, et al：Epidemiological study of gastroentero-pancreatic neuroendocrine tumors in Japan. J Gastroenterol 45：234-243, 2010

42）Tirosh A, El Lakis M, Green P, et al：In silico VHL gene mutation analysis and prognosis of pancreatic neuroendocrine tumors in von Hippel-Lindau disease. J Clin Endocrinol Metab 103：1631-1638, 2018

43）de Mestier L, Gaujoux S, Cros J, et al：Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place. Ann Surg 262：384-388, 2015

44）Kwon T, Jeong IG, Pak S, et al：Renal tumor size is an independent prognostic factor for overall survival in von Hippel-Lindau disease. J Cancer Res Clin Oncol 140：1171-1177, 2014